A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

The introduction of posttransplant cyclophosphamide (PTCy) made performing allogeneic hematopoietic cell transplantation (HCT) from HLA haplotype–incompatible donors possible. In a setting of PTCy and tacrolimus/mycophenolate mofetil (MMF) as a graft-versus-host disease (GVHD) prophylaxis, a periphe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Bejanyan, Nelli, Pidala, Joseph A., Wang, Xuefeng, Thapa, Ram, Nishihori, Taiga, Elmariah, Hany, Lazaryan, Aleksandr, Khimani, Farhad, Davila, Marco L., Mishra, Asmita, Faramand, Rawan, Jain, Michael D., Ochoa, Leonel, Perez, Lia Elena, Liu, Hien, Alsina, Melissa, Kharfan-Dabaja, Mohamed A., Fernandez, Hugo, Nieder, Michael L., Locke, Frederick L., Anasetti, Claudio, Ayala, Ernesto
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7948297/
https://ncbi.nlm.nih.gov/pubmed/33635333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003779
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados